With The Launch Of Yervoy, Early Signs Of R&D Success For Bristol

Four years ago, Bristol management changed course and established the company as a pure play biopharma. Now, with the launch of Yervoy for metastatic melanoma and a late-stage pipeline that is chock-full, the strategy appears about to pay off. CEO Lamberto Andreotti and R&D president Elliott Sigal talked with IN VIVO about the launch of Yervoy and how Bristol, relying on R&D productivity, not diversification, is on track to overcome the extensive patent losses ahead.